Jeffrey W. Albers Sells 20,000 Shares of Blueprint Medicines Corp (BPMC) Stock

Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $63.49, for a total value of $1,269,800.00. Following the transaction, the chief executive officer now directly owns 20,000 shares in the company, valued at approximately $1,269,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BPMC stock opened at $63.29 on Friday. Blueprint Medicines Corp has a 12-month low of $57.44 and a 12-month high of $109.00. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.87 million. During the same quarter in the previous year, the business posted ($0.96) earnings per share. Blueprint Medicines’s revenue was down 86.4% on a year-over-year basis. As a group, equities analysts forecast that Blueprint Medicines Corp will post -5.25 EPS for the current year.

Several hedge funds have recently bought and sold shares of BPMC. NumerixS Investment Technologies Inc raised its position in shares of Blueprint Medicines by 750.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,100 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 4,500 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Blueprint Medicines by 7.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 25,236 shares of the biotechnology company’s stock worth $1,602,000 after purchasing an additional 1,740 shares during the last quarter. grace capital acquired a new position in shares of Blueprint Medicines during the 2nd quarter worth approximately $171,000. Bollard Group LLC raised its position in shares of Blueprint Medicines by 38.6% during the 2nd quarter. Bollard Group LLC now owns 53,000 shares of the biotechnology company’s stock worth $3,364,000 after purchasing an additional 14,750 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Blueprint Medicines by 1.9% during the 2nd quarter. BlackRock Inc. now owns 3,321,905 shares of the biotechnology company’s stock worth $210,876,000 after purchasing an additional 63,392 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

BPMC has been the topic of a number of research reports. ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Wedbush restated an “outperform” rating and issued a $101.00 price objective on shares of Blueprint Medicines in a research report on Monday, October 8th. Zacks Investment Research downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. Leerink Swann started coverage on shares of Blueprint Medicines in a research report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 price objective for the company. Finally, BidaskClub upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $97.14.

TRADEMARK VIOLATION NOTICE: “Jeffrey W. Albers Sells 20,000 Shares of Blueprint Medicines Corp (BPMC) Stock” was first published by WKRB News and is the property of of WKRB News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.wkrb13.com/2018/11/09/jeffrey-w-albers-sells-20000-shares-of-blueprint-medicines-corp-bpmc-stock.html.

About Blueprint Medicines

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Further Reading: Stock Selection – What is cash flow?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply